Login / Signup

Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas.

Eva LhuissierJuliette Aury-LandasMarion LentéKarim BoumedieneCatherine Baugé
Published in: Cancers (2021)
Our results show that DZNep exposure can presensitize chondrosarcoma cells to a standard anticancer drug, emphasizing the promising clinical utilities of epigenetic-chemotherapeutic drug combinations in the future treatment of chondrosarcomas.
Keyphrases
  • dna methylation
  • gene expression
  • adverse drug
  • oxidative stress
  • cell proliferation
  • bone marrow
  • endoplasmic reticulum stress